Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Jul 20, 2019
Open Peer Review Period: Jul 22, 2019 - Jul 29, 2019
Date Accepted: Aug 21, 2019
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis

del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, Valero-Pérez E, Béjar-Serrano S, Aguas M

Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis

J Med Internet Res 2019;21(9):e15505

DOI: 10.2196/15505

PMID: 31538948

PMCID: 6754696

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The cost-effectiveness of telemonitoring complex inflammatory bowel disease using the web-based telemanagement system TECCU

  • Javier del Hoyo; 
  • Pilar Nos; 
  • Guillermo Bastida; 
  • Raquel Faubel; 
  • Diana Muñoz; 
  • Alejandro Garrido-Marín; 
  • Elena Valero-Pérez; 
  • Sergio Béjar-Serrano; 
  • Mariam Aguas

ABSTRACT

Background:

Although eHealth interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease (IBD) is lacking.

Objective:

We aimed to evaluate the cost-effectiveness and cost-utility of the TECCU web platform (G_TECCU) for telemonitoring complex IBD, compared with standard care (G_Control) and nurse-assisted telephone care (G_NT).

Methods:

We performed a cost-effectiveness analysis from a societal perspective, comparing the 3 follow-up methods in a 24-week randomized controlled trial, conducted at a tertiary university hospital in Spain. IBD patients who initiated immunosuppressants and/or biological agents to control inflammatory activity were recruited consecutively. The effects on disease activity (using clinical indexes) and the quality-adjusted life-years (QALYs; using the EuroQol-5D) were collected. We calculated costs of healthcare, equipment and patients´ productivity and social activity impairment. The mean costs per-patient, utilities and bootstrapped differences were compared.

Results:

Sixty-three patients were included (21 patients/group). TECCU saved -1005€ per additional patient in remission compared to G_control (95% CI, -8823 to 17230€), with a 79.96% probability of being more effective at lower costs. Compared with G_NT, TECCU saved -2250€/additional patient (95% CI, -4280 to 3905), whereas G_NT saved -538€ compared to G_control (95% CI -6475 to 5303). QALYs improved less in G_TECCU and G_NT, yet these interventions showed 84% and 67% probability, respectively, of being cost-saving per additional QALY compared with G_control.

Conclusions:

TECCU web platform is probably more cost-effective than standard and telephone care in the short-term. Further research considering larger cohorts and longer time-horizons is required. Clinical Trial: ClinicalTrials.gov NCT02943538


 Citation

Please cite as:

del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, Valero-Pérez E, Béjar-Serrano S, Aguas M

Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis

J Med Internet Res 2019;21(9):e15505

DOI: 10.2196/15505

PMID: 31538948

PMCID: 6754696

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.